Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 8/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1114367 | 0.89 | NPC1 (0.79) | NPC1MAPTCYP3A4ALDH1A1SMN1; SMN2 | |
| SCHEMBL8076355 | 0.89 | NPC1 (0.79) | NPC1MAPTALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL11170918 | 0.85 | NPC1 (0.74) | NPC1MAPTCYP3A4SMN1; SMN2POLB | |
| SCHEMBL13144461 | 0.84 | NPC1 (0.73) | NPC1MAPTALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL584234 | 0.83 | NPC1 (0.71) | NPC1MAPTALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL5095881 | 0.83 | NPC1 (0.71) | NPC1MAPTALDH1A1SMN1; SMN2POLB | |
| SCHEMBL7683393 | 0.83 | NPC1 (0.71) | NPC1MAPTALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL1997115 | 0.83 | NPC1 (0.70) | NPC1MAPTLMNACYP3A4ALDH1A1 | |
| SCHEMBL584503 | 0.82 | NPC1 (0.69) | NPC1MAPTALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL3266105 | 0.82 | NPC1 (0.69) | NPC1MAPTLMNAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9173869-B2 | Mediators of hedgehog signaling pathways, compositions and uses related thereto | CURIS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140107125-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | DERMIRA (CANADA), INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8445694-B2 | Hydrazonopyrazole derivatives and their use as therapeutics | DERMIRA (CANADA), INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8354397-B2 | Controlling cell differentiation, cell proliferation; anticancer agents | CURIS, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8129425-B2 | Contacting cell with hedgehog antagonist; moderator of cell proliferative, cell differentiation | CURIS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20110237783-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | Valocor Therapeutics, Inc. (CA) | 2011-09-29 | — | — | US | disclosed |
| US-7875728-B2 | tert-butyl-[5-methyl-4-(phenylhydrazono)-4H-pyrazol-3-yl]amine; 4-(3-fluorophenylhydrazono)-5-methyl-2H-pyrazol-3-ylamine; demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death | Valocor Therapeutics, Inc. (CA) | 2011-01-25 | — | — | US | disclosed |
| US-7786125-B2 | Neuroprotective small organic molecules, compositions and uses of related thereto | LIN LEU-FEN H | 2010-08-31 | — | — | US | disclosed |
| US-7671077-B2 | Neuroprotective small organic molecules, compositions and uses related thereto | LIN LEU-FEN HOU | 2010-03-02 | — | — | US | disclosed |
| EP-1482928-B1 | MEDIATORS OF HEDGEHOG SIGNALING PATHWAYS,COMPOSITIONS AND USES RELATED THERETO | CURIS INC (US) | 2009-09-23 | — | — | EP | disclosed |
| EP-1670763-A1 | CYCLOPENTENE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-06-21 | — | — | EP | disclosed |
| US-20050272709-A1 | Immugenic compositions and diagnostic and therapeutic uses thereof | DERMIRA (CANADA), INC. | 2005-12-08 | — | — | US | disclosed |
| WO-2005037793-A1 | CYCLOPENTENE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | WO | disclosed |
| US-20050070578-A1 | Small organic molecule regulators of cell proliferation | CURIS, INC. | 2005-03-31 | — | — | US | disclosed |
| EP-1450791-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | Kinetek Pharmaceuticals, Inc. (CA) | 2004-09-01 | — | — | EP | disclosed |
| EP-1013636-B1 | Preparation of allylic aromatic compounds | AMERSHAM HEALTH AS (NO) | 2003-07-09 | — | — | EP | disclosed |
| WO-2003045379-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | KINETEK PHARMACEUTICALS, INC. (CA) | 2003-06-05 | — | — | WO | disclosed |
| US-20030060453-A1 | Pyrazole compounds | DERMIRA (CANADA), INC. | 2003-03-27 | — | — | US | disclosed |
| US-6284894-B1 | AROMATIC AMINE IS REACTED FIRST WITH A NITRITE AND THEN WITH AN ALLYLIC OLEFIN HAVING AN ELIMINATABLE TERMINAL SUBSTITUENT. | NYCOMED IMAGING AS (NO) | 2001-09-04 | — | — | US | disclosed |
| EP-1013636-A1 | Preparation of allylic aromatic compounds | NYCOMED IMAGING AS (NO) | 2000-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237783-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | CDK4, CCNI, BCL2 | NPC1 2611/4885MAPT 4573/4885LMNA 2013/4885 |
| US-20140107125-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | CDK4, CCNI, BCL2 | NPC1 2611/4885MAPT 4573/4885LMNA 2013/4885 |
| US-20050272709-A1 | Immugenic compositions and diagnostic and therapeutic uses thereof | MKI67, CDK4, CCNC | NPC1 3205/4885MAPT 4000/4885LMNA 561/4885 |
| US-20030060453-A1 | Pyrazole compounds | CCNC, MKI67, CDC25C | NPC1 2227/4885MAPT 4486/4885LMNA 1653/4885 |
| US-20050070578-A1 | Small organic molecule regulators of cell proliferation | GLI1, SHH, SMO | NPC1 3715/4885MAPT 4567/4885LMNA 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.